



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## NG 52

Cat. No.:	HY-15154
CAS No.:	212779-48-1
Molecular Formula:	C <sub>16</sub> H <sub>19</sub> ClN <sub>6</sub> O
Molecular Weight:	346.81
Target:	CDK
Pathway:	Cell Cycle/DNA Damage
Storage:	Powder    -20°C    3 years 4°C    2 years In solvent   -80°C    2 years -20°C    1 year



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 75 mg/mL (216.26 mM; Need ultrasonic)					
	Preparing Stock Solutions	<div><div>Solvent</div><div>Concentration</div></div>	Mass	1 mg	5 mg	10 mg
		1 mM		2.8834 mL	14.4171 mL	28.8342 mL
		5 mM		0.5767 mL	2.8834 mL	5.7668 mL
		10 mM		0.2883 mL	1.4417 mL	2.8834 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.21 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.21 mM); Clear solution					

### BIOLOGICAL ACTIVITY

Description	NG 52 is a potent, cell-permeable, selective, ATP-compatible and orally active Cdc28p and Pho85p kinase inhibitor with IC <sub>50</sub> s of 7 μM and 2 μM, respectively. NG 52 also inhibits the activity of phosphoglycerate kinase 1 (PGK1) with an IC <sub>50</sub> of 2.5 μM. NG 52 is inactive against yeast kinases Kin28p, Srb10, and Cak1p <sup>[1][2]</sup> .			
IC <sub>50</sub> & Target	cdc2-cyclin B 0.34 μM (IC <sub>50</sub> )	Pho85p 2 nM (IC <sub>50</sub> )	Cdc28p 7 μM (IC <sub>50</sub> )	Phosphoglycerate kinase 1 (PGK1) 2.5 μM (IC <sub>50</sub> )
In Vitro	NG 52 (Compound 52) inhibits growth in a drug-sensitized yeast strain ( <i>S. cerevisiae</i> ) with a GI <sub>50</sub> of 30 μM. NG 52 is active against cdc2-cyclin B with an IC <sub>50</sub> value of 340 nM <sup>[1]</sup> .			

NG 52 dose-dependently inhibits the proliferation of glioma U87 and U251 cell lines with  $GI_{50}$  values of 7.8  $\mu$ M and 5.2  $\mu$ M, respectively, meanwhile it potently inhibits the proliferation of primary glioma cells<sup>[2]</sup>.  
NG 52 (12.5-50  $\mu$ M) effectively inhibits the phosphorylation of PDHK1 at Thr338 site and the phosphorylation of PDH at Ser293 site in U87 and U251 cells, resulting in more pyruvic acid entering the Krebs cycle with increased production of ATP and ROS<sup>[2]</sup>.

NG 52 can reverse the Warburg effect by enhancing the activity of pyruvate dehydrogenase (PDH) through inhibiting the activity of PGK1, and switched cellular glucose metabolism from anaerobic mode to aerobic mode<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Cell Proliferation Assay<sup>[2]</sup>

Cell Line:	Glioma U87 and U251 cells
Concentration:	0 $\mu$ M, 12.5 $\mu$ M, 25 $\mu$ M, 50 $\mu$ M
Incubation Time:	6 days
Result:	Potently inhibited the proliferation of primary glioma cells.

#### Western Blot Analysis<sup>[2]</sup>

Cell Line:	Glioma U87 and U251 cells
Concentration:	0 $\mu$ M, 12.5 $\mu$ M, 25 $\mu$ M, 50 $\mu$ M
Incubation Time:	12 hours or 24 hours
Result:	Potently inhibited the proliferation of primary glioma cells.

#### In Vivo

NG 52 (50-150 mg/kg; oral administration; daily; for 13 days) treatment dose-dependently suppresses the growth of glioma xenograft<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female nu/nu mice (5-week-old) injected with glioma cells <sup>[2]</sup>
Dosage:	50 mg/kg, 100 mg/kg, 150 mg/kg
Administration:	Oral administration; daily; for 13 days
Result:	Dose-dependently suppressed the growth of glioma xenograft.

#### CUSTOMER VALIDATION

- Acta Pharmacol Sin. 2020 Jul 31.
- Food Chem X. 2024 Jan 9, 101125.
- J Appl Physiol (1985). 2023 Jun 29.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

#### REFERENCES

- [1]. ray NS, Wodicka L, Thunnissen AM et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 1998 Jul 24;281(5376):533-8.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA